1205 Dolasetron (DOL) vs ondansetron (OND) with and without dexamethasone (DEX) in the prevention of nausea (N) and vomiting (V) in patients (PTS) receiving moderately emetogenic chemotherapy (MEC)

Lofters, W.; Zee, B.

doi:10.1016/0959-8049(95)96451-i

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with breast cancer seemed to have less fatigue and those with ovarian and lung cancer more, even when the effects of other characteristics were taken into account. Finally, in an effort to determine whether longitudinally collected fatigue data were sensitive to differences in treatment efficacy, we examined changes in fatigue scores in patients on an anti-emetic trial in which the use of dexamethasone had been shown to provide substantially improved control of post-chemotherapy emesis [4]. As displayed in Fig.…”

Section: Resultsmentioning

confidence: 99%

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

Pater

Zee

Palmer

et al. 1997

Support Care Cancer

View full text Add to dashboard Cite

The purpose of this study was to examine the factors which affect the level of fatigue among patients participating in clinical trials in which this symptom had been assessed with the EORTC QLQ-C30. Data were assembled from 2390 patients in ten clinical trials in which the QLQ-C30 had been used to assess baseline and on-study quality of life. The relationship between the level of fatigue reported by the patients on the fatigue scale of this questionnaire and patient and disease characteristics was assessed in univariate and multivariate cross-sectional analyses. In addition, changes in fatigue scores were compared in a longitudinal analysis among patients on two arms of an anti-emetic trial whose emesis control was markedly different. Baseline fatigue levels differed substantially among patients taking part in the different trials. Factors associated with greater fatigue severity on univariate analysis included: female gender, presence of metastatic disease, and poorer performance status. In addition, on multivariate analyses the oldest patients were found to have less fatigue, as were patients with breast cancer, while patients with ovarian and lung cancer experienced greater fatigue. Patients on the arm of the anti-emetic trial in which emesis was better controlled showed significantly less increase in fatigue after receiving chemotherapy. The fatigue scale of the QLQ-C30 appears to provide a useful approach to assessing this important symptom. The relationships found between fatigue and patient and disease characteristics need further exploration as does the degree to which the QLQ-C30 fully captures this dimension of quality of life.

show abstract

Section: Resultsmentioning

confidence: 99%

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

Pater

Zee

Palmer

et al. 1997

Support Care Cancer

View full text Add to dashboard Cite

show abstract

The effect of food on the bioavailability of dolasetron mesylate tablets

Lippert¹,

Keung²,

Arumugham³

et al. 1998

Biopharm & Drug Disp

View full text Add to dashboard Cite

Anzemet® (dolasetron mesylate) is being developed for the prevention of chemotherapy‐induced emesis and postoperative nausea and vomiting. Twenty‐four healthy male subjects were orally dosed with dolasetron mesylate, 200 mg, after either an overnight fast or a high‐fat breakfast. The ratio of the mean area under the plasma concentration–time curve of the reduced active metabolite (MDL 74 156) to infinity (AUC(0–∞)) values in fed compared to fasting subjects was 86.3% with a 90% confidence interval for the ratio within (80, 125)%, indicating bioequivalence. The ratio of the mean MDL 74 156 maximum plasma concentration (Cmax) values was 70.6% in fed versus fasted subjects. The time to Cmax was statistically significantly longer after the high‐fat breakfast (mean values, 1.11 h fasting and 1.80 h fed), probably due to delayed gastric emptying. It may be concluded that, although the rate of absorption was somewhat delayed, the extent of absorption did not change significantly when dolasetron mesylate was given with food. © 1998 John Wiley & Sons, Ltd.

show abstract

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis

Piechotta

Adams

Haque

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

1205 Dolasetron (DOL) vs ondansetron (OND) with and without dexamethasone (DEX) in the prevention of nausea (N) and vomiting (V) in patients (PTS) receiving moderately emetogenic chemotherapy (MEC)

Cited by 4 publications

References 0 publications

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

The effect of food on the bioavailability of dolasetron mesylate tablets

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis

Contact Info

Product

Resources

About